Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...

Shares of Abbott Laboratories (NYSE:ABT) lost ~5% in the premarket on Thursday after the MedTech company provided its ...

Q2 2025 Earnings Call Transcript July 17, 2025 Abbott Laboratories reports earnings inline with expectations. Reported EPS is ...

Abbott did not factor in the decision during Sunday's loss to the Mets. He allowed two runs on six hits and a walk over six innings while striking out five.

Investing.com -- Jefferies upgraded Abbott Laboratories (NYSE: ABT) to Buy from Hold, calling the market reaction to the ...

"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly ...

Abbott Laboratories stock tumbled Thursday after the maker of medical devices and nutrition products narrowed its full-year ...

Abbott Laboratories closed 6.52% below its 52-week high of $141.23, which the company reached on March 4th.

Abbott Laboratories’ Debt totaled $15 Bil at the end of the latest quarter, while its market capitalization stands at $233 ...

Discover Abbott Laboratories' Q2 2025 highlights: resilience drives high single-digit growth, double-digit EPS, and pipeline innovations.

Here is how Abbott (ABT) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.

Importantly, Abbott Laboratories (NYSE:ABT) does carry debt. But the real question is whether this debt is making the company risky. Debt assists a business until the business has trouble paying it ...